BNP Paribas Funds Health Care Innovators Classic Capitalisation
Equity fund
1 year
USA
Largest region
Medium
Risk
Annual costs
Morningstar
Partial
Sustainability
Development
Last 5 years
( ann.)
Description
- The investment objective of the fund is to increase the value of its assets over the medium term by investing in healthcare innovative companies.
Investment horizon
- BNP Paribas Funds Health Care Innovators Classic Capitalisation is a Equity fund. This mutual fund type is suitable for those who plan to save for at least 6 years.
Characteristics
- Minimum amount
- Sharpe 3 years
- Price/NAV
21 Jul 2025
- Start date16 May 2013
- ISINLU0823416762
Risk
- Medium (4 of 7)
Morningstar rating
- The Morningstar Rating is an objective standard that tells us how well a fund has done compared to similar funds. If a fund performs better than other funds it is compared with, it receives a high rating. Correspondingly, a fund receives a low rating if it performs worse than similar funds.
Sustainability
- SustainabilityPartial
Costs
- Ongoing costs
Includes management fees of 1,50 %
- Platform fee
- Kickback fee
- Annual running costs
- Performance-based fee
Any transaction costs to the manager are not included in the cost overview. These are stated under cost details on the summary page before you purchase the fund. Costs for any currency exchanges are not included.
Allocation
- Stocks 98%Interest 2%
Portfolio
Shows the fund's largest investments.
- AstraZeneca PLC7.6%
- Eli Lilly and Co7.0%
- Sanofi SA5.5%
- Boston Scientific Corp4.9%
- Intuitive Surgical Inc4.3%
- Neurocrine Biosciences Inc4.1%
- Gilead Sciences Inc4.0%
- Vertex Pharmaceuticals Inc3.6%
- UnitedHealth Group Inc3.5%
- Regeneron Pharmaceuticals Inc3.4%